Avanos Medical Inc

Avanos Medical, Inc. operates as a medical technology company. It focuses on delivering clinically medical device solutions to improve patients' quality of life. The firm’s portfolio of product offerings focuses on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avanos Medical Inc reports robust Q4 results and outlines growth strategies

Avanos Medical Inc delivered strong financial performance in Q4 2022, showcasing growth in key product categories and exceeding expectations in OrthogenRx. While facing challenges in certain segments, Avanos is focused on optimizing operations and capitalizing on identified opportunities for growth.

Avanos Medical reports steady Q1 performance amidst strategic transformation

Avanos Medical Inc's Q1 2023 performance was steady, with a focus on operational efficiency and profitability enhancement.
While facing challenges in certain product categories, Avanos is well-positioned to capitalize on growth opportunities through strategic initiatives.
The company's transformation priorities and guidance for the year reflect a proactive approach to navigating market dynamics and driving sustainable value creation.

Avanos Medical Inc reports resilient Q2 performance and outlines growth strategies

Avanos Medical Inc demonstrated resilience in Q2 amidst supply chain challenges and inflation effects.
The company's focus on strategic priorities and shareholder value enhancement initiatives bode well for future growth.
Despite some portfolio challenges, Avanos remains optimistic about mid-single-digit revenue growth in 2024.
Operational efficiency and growth opportunities in key product lines position Avanos for sustained success.

Avanos Medical Inc reports Q3 results, focuses on efficiency and growth

Avanos Medical Inc's Q3 performance reflects mixed results with growth in Digestive Health but decline in Pain Management portfolios.
The company's transformation priorities and cost management efforts aim to drive efficiency and optimize performance.
Despite challenges in certain product segments, Avanos Medical Inc's focus on gross margin improvement and savings targets bode well for future profitability.
Opportunities lie in portfolio transformation, enhanced gross margins, and strategic initiatives like DIros Technology and cost optimization.

Avanos Medical Inc reports stable Q4 earnings amidst growth strategies

Avanos Medical Inc's Q4 performance reflects mixed results with challenges in certain product segments but stable profitability.
The company's strategic priorities aim to drive future growth through portfolio optimization and cost management.
Anticipated revenue growth, focus on M&A, and long-term financial targets position Avanos for sustainable performance and expansion.

Avanos Medical Inc reports solid Q1 performance and growth outlook

Avanos Medical Inc's Q1 2024 performance showed mixed results across portfolios but strong overall financials.
The company's focus on cost management, capital efficiency, and strategic targets bodes well for future growth.
Despite challenges in certain product lines, Avanos remains confident in its strategies and growth trajectory.

Avanos Medical reports resilient Q2 results amidst portfolio growth

Avanos Medical's Q2 performance showcased solid sales figures and growth in key portfolios, despite challenges in certain segments.
The company's strengths lie in maintaining financial guidance, a strong balance sheet, and a strategic focus on transformation initiatives.
While facing challenges in specific product lines, Avanos Medical has opportunities to drive growth through product innovation, strategic partnerships, and capital allocation.
Overall, Avanos Medical remains committed to its transformation journey and delivering value to shareholders through prudent financial management.

Avanos Medical reports Q3 results, focuses on growth strategies

Avanos Medical's Q3 performance reflects a mixed picture with strong Digestive Health growth but challenges in the pain portfolio.
The company's strategic focus on high-margin products, cost management, and growth initiatives positions it for future success.
Despite current challenges, Avanos Medical's pursuit of organic growth, efficient capital allocation, and strategic M&A bode well for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avanos Medical, Inc. is a medical technology company, which engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock?

Avanos Medical (AVNS) Down 14% Since Last Earnings Report: Can It Rebound?

ALPHARETTA, Ga. , Sept. 7, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody, chief executive officer, and Michael Greiner, senior vice president and chief financial officer, will present and participate in an analyst-led fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, Sept.

Avanos Medical, Inc. To Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Avanos Medical, Inc. (NYSE:AVNS ) Q2 2022 Earnings Conference Call August 9, 2022 9:00 AM ET Company Participants Scott Galovan - Vice President, Corporate Strategy and Business Development Joe Woody - Chief Executive Officer Michael Greiner - Senior Vice President and Chief Financial Officer Conference Call Participants Rick Wise - Stifel Matthew Mishan - KeyBanc Chris Cooley - Stephens Drew Ranieri - Morgan Stanley Operator Good day, and welcome to Avanos Second Quarter 2020 Earnings Call. All participants will be in a listen-only mode.

Avanos Medical, Inc. (AVNS) CEO Joe Woody on Q2 2022 Results - Earnings Call Transcript

ACM Research

Brookdale Senior Living

Green Plains

MagnaChip Semiconductor

Shutterstock

Smith & Wesson Brands

Let's begin by defining the realm of small-cap stocks before we discuss those that appear to be strong, safe investments currently. As their name implies, small-cap stocks have lower market capitalizations than both mid-cap and large-cap stocks.

7 Safe Small-Cap Stocks to Buy Now

Avanos's (AVNS) second-quarter 2022 results reflect strength in the Pain Management segment.

Avanos (AVNS) Q2 Earnings Top Estimates, FY22 View Lowered

Avanos Medical (AVNS) delivered earnings and revenue surprises of 5.13% and 2.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) Surpasses Q2 Earnings Estimates

ALPHARETTA, Ga. , Aug. 9, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2022 financial results.

Avanos Medical, Inc. Announces Second Quarter 2022 Results

ALPHARETTA, Ga. , July 27, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2022 on Tuesday, August 9 at 9 a.m.

Avanos Medical, Inc. to Webcast Conference Call Discussing Second Quarter 2022 Financial Results

Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avanos Medical (AVNS) to Report Q2 Results: Wall Street Expects Earnings Growth

Boise Cascade

Griffon

John Bean Technologies

Proto Labs

Sonos

These undervalued small-cap stocks to buy do have value and could outperform in both the short term and long term. The post 7 Undervalued Small-Cap Stocks to Buy Now appeared first on InvestorPlace.

7 Undervalued Small-Cap Stocks to Buy Now

Avanos Medical (AVNS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Avanos Medical (AVNS) Keep the Earnings Surprise Streak Alive?

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Here's Why You Should Hold on to Avanos (AVNS) Stock For Now

ALPHARETTA, Ga. , May 17, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, senior vice president and chief financial officer, will present and participate in a fireside chat at the UBS 2022 Global Healthcare Conference on Monday, May 23 at approximately 1:15 p.m.

Avanos Medical, Inc. to Present at the UBS 2022 Global Healthcare Conference

Avanos Medical, Inc. (NYSE:AVNS ) Q1 2022 Earnings Conference Call May 7, 2022 9:00 AM ET Company Participants Scott Galovan - Vice President, Corporate Strategy and Business Development Joe Woody - Chief Executive Officer Michael Greiner - Senior Vice President and Chief Financial Officer Conference Call Participants Chris Cooley - Stephens Matthew Mishan - KeyBanc Rick Wise - Stifel Drew Ranieri - Morgan Stanley Operator Good morning. And welcome to Avanos First Quarter 2022 Earnings Call.

Avanos Medical, Inc. (AVNS) CEO Joe Woody on Q1 2022 Results - Earnings Call Transcript

Avanos Medical's (AVNS) first-quarter 2022 results reflect strength in the Pain Management segment.

Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates

Avanos Medical (AVNS) delivered earnings and revenue surprises of 8.33% and 0.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates

ALPHARETTA, Ga. , May 4, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2022 financial results.

Avanos Medical, Inc. Announces First Quarter 2022 Results

ALPHARETTA, Ga. , April 27, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2021 on Wednesday, May 4 at 9 a.m.

Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2022 Financial Results

Here is how Avanos Medical (AVNS) and Axcella Health Inc. (AXLA) have performed compared to their sector so far this year.

Is Avanos Medical (AVNS) Stock Outpacing Its Medical Peers This Year?

ALPHARETTA, Ga., March 15, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody, chief executive officer, and Michael Greiner, senior vice president and chief financial officer, will present and participate in an analyst-led fireside chat at the virtual KeyBanc 2022 Life Sciences & MedTech Investor Forum on Tues.

Avanos Medical, Inc. to Present at the Virtual KeyBanc 2022 Life Sciences & MedTech Investor Forum

The mean of analysts' price targets for Avanos Medical (AVNS) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Avanos Medical (AVNS) Have the Potential to Rally 26% as Wall Street Analysts Expect?

Avanos Medical's (AVNS) fourth-quarter 2021 results gain from strength in the chronic care segment.

Avanos Medical (AVNS) Q4 Earnings, Revenues Top Estimates

Avanos Medical's (AVNS) CEO Joe Woody on Q4 2021 Results - Earnings Call Transcript

Avanos Medical (AVNS) delivered earnings and revenue surprises of 15% and 1.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) Beats Q4 Earnings and Revenue Estimates

ALPHARETTA, Ga., Feb. 23, 2022 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2021 results.

News for Avanos Medical Inc Stock (AVNS)